OBJECTIVE: To determine serum levels of monocyte chemotactic protein-3 (MCP-3) and its clinical associations in patients with systemic sclerosis (SSc). METHODS: Serum MCP-3 levels from 69 patients with SSc were examined by ELISA. RESULTS: Serum MCP-3 levels were raised in patients with SSc (n = 69) compared with healthy controls (n = 28). Patients with diffuse cutaneous SSc (n = 36) had higher levels of serum MCP-3 than those with limited cutaneous SSc (n = 33). Patients with raised MCP-3 levels had pulmonary fibrosis and decreased vital capacity (VC) more often than those with normal MCP-3 levels. MCP-3 levels correlated positively with the extent of skin fibrosis, and inversely with %VC and carbon monoxide transfer factor (Tlco) in patients with SSc. CONCLUSION: MCP-3 levels were increased in patients with SSc, and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis. These results suggest that MCP-3 may have a role in the development of fibrosis in SSc.
OBJECTIVE: To determine serum levels of monocyte chemotactic protein-3 (MCP-3) and its clinical associations in patients with systemic sclerosis (SSc). METHODS: Serum MCP-3 levels from 69 patients with SSc were examined by ELISA. RESULTS: Serum MCP-3 levels were raised in patients with SSc (n = 69) compared with healthy controls (n = 28). Patients with diffuse cutaneous SSc (n = 36) had higher levels of serum MCP-3 than those with limited cutaneous SSc (n = 33). Patients with raised MCP-3 levels had pulmonary fibrosis and decreased vital capacity (VC) more often than those with normal MCP-3 levels. MCP-3 levels correlated positively with the extent of skin fibrosis, and inversely with %VC and carbon monoxide transfer factor (Tlco) in patients with SSc. CONCLUSION:MCP-3 levels were increased in patients with SSc, and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis. These results suggest that MCP-3 may have a role in the development of fibrosis in SSc.
Authors: N Kaminski; J D Allard; J F Pittet; F Zuo; M J Griffiths; D Morris; X Huang; D Sheppard; R A Heller Journal: Proc Natl Acad Sci U S A Date: 2000-02-15 Impact factor: 11.205
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: Irina G Luzina; Sergei P Atamas; Robert Wise; Fredrick M Wigley; Hui Qing Xiao; Barbara White Journal: Am J Respir Cell Mol Biol Date: 2002-05 Impact factor: 6.914
Authors: Voon H Ong; Lowri A Evans; Xu Shiwen; Ivan B Fisher; Vineeth Rajkumar; David J Abraham; Carol M Black; Christopher P Denton Journal: Arthritis Rheum Date: 2003-07
Authors: Kristina En Clark; Henry Lopez; Bahja Ahmed Abdi; Sandra G Guerra; Xu Shiwen; Korsa Khan; Oseme Etomi; George R Martin; David J Abraham; Christopher P Denton; Richard J Stratton Journal: Arthritis Res Ther Date: 2015-03-23 Impact factor: 5.156
Authors: Rebecca Lee; Charles Reese; Beth Perry; Jonathan Heywood; Michael Bonner; Marina Zemskova; Richard M Silver; Stanley Hoffman; Elena Tourkina Journal: Fibrogenesis Tissue Repair Date: 2015-06-20
Authors: Dimitrios Kalafatis; Anna Löfdahl; Per Näsman; Göran Dellgren; Åsa M Wheelock; Linda Elowsson Rendin; Magnus Sköld; Gunilla Westergren-Thorsson Journal: Int J Mol Sci Date: 2021-12-14 Impact factor: 5.923